# Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study

Source: https://onco.cc/key-papers/paper-nct06015503-j-thorac-oncol-2026/  
OnCo record `paper-nct06015503-j-thorac-oncol-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the KANNON trial registered as NCT06015503, in Journal of Thoracic Oncology (2026), chosen as the most cited paper whose own text cites the registry id.

## Summary

Objectives: This study aimed to evaluate andamertinib, a selective and irreversible tyrosine kinase inhibitor, in pretreated advanced EGFR exon 20 insertion (ex20ins)-mutant NSCLC.

Methods: In the phase 2, multicenter, single-arm KANNON study (NCT06015503), patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who had progressed after platinum-based chemotherapy or immunotherapy received oral andamertinib 240 mg once daily in 28-day cycles. The primary end point was the confirmed objective response rate (ORR) assessed by independent review.

Results: A total of 92 patients were enrolled and received daily 240 mg andamertinib, with nearly 30 different exon20ins subtypes included. The confirmed ORR was 42.7% (95% confidence interval [CI], 32.4-53.0), with a disease control rate of 86.5% and a median duration of response of 8.7 months (95% CI, 5.65-11.96). at September 6, 2025, with a median follow-up of 15.4 (range, 0.4-20.5) months, the median progression-free survival was 6.2 months (95% CI, 4.63-7.85) and median overall survival was not reached (95% CI, 13.93 mo to not estimable), with a 12-month survival rate of 70.5%. Among 38 patients with brain metastasis, the systemic confirmed ORR was 47.4% (95% CI, 31.5-63.2). Grade more than or equal to 3 treatment-related adverse events occurred in 40.2% of patients, and the most frequent events were diarrhea (12.0%) and rash (7.6%). No interstitial lung disease or grade more than or equal to 3 QT prolongation was reported.

Conclusions: Andamertinib at 240 mg once daily demonstrated efficacy with a manageable safety profile in previously treated patients with EGFR ex20ins-mutant NSCLC.

Indexed on Europe PMC as PubMed record 41248848 (DOI 10.1016/j.jtho.2025.11.008). Its abstract cites the registry id NCT06015503, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Journal of Thoracic Oncology
- Year: 2026
- DOI: 10.1016/j.jtho.2025.11.008
- Authors: Yang JJ, Mu Y, Wang ZH, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT06015503 with the most citations, so it is the natural first reading for anyone following the KANNON trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- J Thorac Oncol 2026: https://doi.org/10.1016/j.jtho.2025.11.008
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41248848/
- Europe PMC: https://europepmc.org/article/MED/41248848
- ClinicalTrials.gov NCT06015503: https://clinicaltrials.gov/study/NCT06015503

## Connected records

- trials: [A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06015503/)
- journals: [Journal of Thoracic Oncology](https://onco.cc/journals/journal-of-thoracic-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct06015503-j-thorac-oncol-2026.json